Kestra Medical Technologies, Ltd. (Ticker: KMTS US), a Bermuda-incorporated company specializing in wearable cardioverter defibrillators (WCDs), plans to list on NASDAQ on March 6, 2025. Kestra’s IPO was upsized from 10.0 million shares to 11.88 million, and priced at $17, above a price range of $14.00-$16.00, aiming to raise $202 million. The company's ASSURE WCD product, launched in 2022, is used in over 550 U.S. hospitals.

The offering is managed by BofA Securities, Goldman Sachs, Piper Sandler, Wells Fargo Securities and Stifel. Kestra reported revenue of $45.8 million and a net loss of $84.8 million for the 12 months ended Oct. 31, 2024, market cap is $714.75 million.